drugset / Trial / NCT02580539
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.
Timeline
- Start
- 2015-11
- Primary completion
- 2025-05
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peptide-stimulated T cells | Cell therapy | 2e+07 unknown | Other |
| Subject | Peptide-stimulated T cells | Cell therapy | — | Other |